{
    "clinical_study": {
        "@rank": "157987", 
        "arm_group": {
            "arm_group_label": "Pasireotide", 
            "arm_group_type": "Experimental", 
            "description": "Pasireotide subcutaneous or Long Acting Release"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to allow continued use of pasireotide in patients who are on\n      pasireotide treatment in a Novartis-sponsored, Oncology Clinical Development & Medical\n      Affairs (CD&MA) study and are benefiting from the treatment as judged by the investigator."
        }, 
        "brief_title": "Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.", 
        "completion_date": {
            "#text": "April 2023", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Cushing's Disease,", 
            "Acromegaly,", 
            "Neuroendocrine Tumors,", 
            "Pituitary Tumors", 
            "Ectopic ACTH Secreting (EAS) Tumors,", 
            "Dumping Syndrome,", 
            "Prostate Cancer,", 
            "Melanoma Negative for bRAF,", 
            "Melanoma Negative for nRAS"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Acromegaly", 
                "Cushing Syndrome", 
                "Pituitary ACTH Hypersecretion", 
                "Dumping Syndrome", 
                "Melanoma", 
                "Pituitary Neoplasms", 
                "Prostatic Neoplasms", 
                "Neuroendocrine Tumors", 
                "Cardiac Complexes, Premature"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a multi-center, open label, phase IV study to provide continued supply of\n      pasireotide to patients being treated in a current Novartis-sponsored, Oncology CD&MA study\n      and who are benefiting from treatment with pasireotide. Eligible patients are to be\n      consented and can then continue treatment with pasireotide in this protocol. All patients at\n      their scheduled visits will have drug dispensing information and reported adverse events and\n      serious adverse events collected.\n\n      A patient will reach the end of study when pasireotide treatment is permanently discontinued\n      and the end of treatment visit has been performed. All patients must be followed up for\n      safety evaluations for 3 months following the last dose of pasireotide LAR treatment and for\n      1 month following the last dose of pasireotide s.c. treatment.\n\n      The study is expected to remain open for approximately 10 years or until such time that\n      enrolled patients no longer need treatment with pasireotide or are able to obtain commercial\n      supply according to local regulations for their medical condition."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient is currently participating in a Novartis Oncology sponsored study receiving\n             pasireotide (LAR and/or s.c.) and has fulfilled all required assessments in the\n             parent study (unless the study is being terminated) and patients that are benefiting\n             from the study drug have no other alternatives\n\n          -  Patient is currently benefiting from the treatment with pasireotide,  as determined\n             by the investigator\n\n          -  Patient has demonstrated compliance, as assessed by the investigator, with the parent\n             study requirements\n\n          -  Willingness and ability to comply with scheduled visits, treatment plans and any\n             other study procedures\n\n          -  Written informed consent obtained prior to enrolling in roll-over study and receiving\n             study medication \u2022 If consent cannot be expressed in writing, it must be formally\n             documented and witnessed, ideally via an independent trusted witness\n\n        Exclusion Criteria:\n\n          -  Patient has been permanently discontinued from pasireotide study treatment in the\n             parent study due to unacceptable toxicity, non-compliance to study procedures,\n             withdrawal of consent or any other reason\n\n          -  Patient has participated in a Novartis sponsored combination trial where pasireotide\n             was dispensed in combination with another study medication and is still receiving\n             combination therapy. (only patients receiving pasireotide monotherapy can be\n             included)\n\n          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a\n             female after conception and until the termination of gestation, confirmed by a\n             positive hCG laboratory test\n\n          -  Women of child-bearing potential, defined as all women physiologically capable of\n             becoming pregnant, unless they are using highly effective methods of contraception\n             during dosing and for 1 months after pasireotide s.c. last dose and 3 months after\n             pasireotide LAR last dose Highly effective contraception methods include:\n\n               -  Total abstinence (when this is in line with the preferred and usual lifestyle of\n                  the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal,\n                  post-ovulation methods) and withdrawal are not acceptable methods of\n                  contraception\n\n               -  Female sterilization (have had surgical bilateral oophorectomy with or without\n                  hysterectomy) or tubal ligation at least six weeks before taking study\n                  treatment. In case of oophorectomy alone, only when the reproductive status of\n                  the woman has been confirmed by follow up hormone level assessment\n\n               -  Male sterilization (at least 6 months prior to screening). For female subjects\n                  on the study the vasectomized male partner should be the sole partner for that\n                  subject.\n\n               -  Combination of any two of the following (a+b or a+c, or b+c):\n\n                    1. Use of oral, injected or implanted hormonal methods of contraception or\n                       other forms of hormonal contraception that have comparable efficacy\n                       (failure rate <1%), for example hormone vaginal ring or transdermal hormone\n                       contraception\n\n                    2. Placement of an intrauterine device (IUD) or intrauterine system (IUS)\n\n                    3. Barrier methods of contraception: Condom or Occlusive cap  diaphragm or\n                       cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal\n                       suppository In case of use of oral contraception women should have been\n                       stable on the same pill for a minimum of 3 months before taking study\n                       treatment\n\n          -  Sexually active males unless they use a condom during intercourse while taking drug\n             and for 1 months after pasireotide s.c. last dose and 3 months after pasireotide LAR\n             last dose and should not father a child in this period. A condom is required to be\n             used also by vasectomized men in order to prevent delivery of the drug via seminal\n             fluid If a study patient or partner becomes pregnant or suspects being pregnant\n             during the study or within 1 month after the final dose of pasireotide s.c. or 3\n             months after the final dose of pasireotide LAR, the Study Doctor needs to be informed\n             immediately and ongoing study treatment with pasireotide has to be stopped\n             immediately For patients taking pasireotide LAR, the future dose injections will be\n             cancelled."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01794793", 
            "org_study_id": "CSOM230B2412"
        }, 
        "intervention": {
            "arm_group_label": "Pasireotide", 
            "description": "Pasireotide subcutaneous or Long Acting Release", 
            "intervention_name": "Pasireotide", 
            "intervention_type": "Drug", 
            "other_name": "SOM230"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "SOM230,", 
            "roll-over study,", 
            "pasireotide LAR,", 
            "Cushing's disease,", 
            "Acromegaly,", 
            "neuroendocrine tumors,", 
            "NETs,", 
            "pituitary tumors,", 
            "Ectopic ACTH secreting,", 
            "EAS,", 
            "Dumping Syndrome,", 
            "metastatic prostate cancer,  metastatic melanoma,", 
            "bRAF,", 
            "nRAS"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Jacob.Edmondson@cshs.org", 
                    "last_name": "Jacob Edmondson", 
                    "phone": "310-423-1047"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90048"
                    }, 
                    "name": "Cedars Sinai Medical Center Cedars Sinai 4"
                }, 
                "investigator": {
                    "last_name": "Edward M. Wolin", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dklebus@stanford.edu", 
                    "last_name": "Daniel Lebus", 
                    "phone": "650-724-4131"
                }, 
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94304"
                    }, 
                    "name": "Stanford University Medical Center Stanford Hospital & Clinics"
                }, 
                "investigator": {
                    "last_name": "Laurence Katznelson", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "cplunket@med.umich.edu", 
                    "last_name": "Cynthia Plunkett", 
                    "phone": "734-936-8065"
                }, 
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109-0944"
                    }, 
                    "name": "University of Michigan Comprehensive Cancer Center SC-2"
                }, 
                "investigator": {
                    "last_name": "Ariel Barkan", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadephia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "University of Pennsylvania Medical Center Univ Penn"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "contact": {
                    "email": "colleen.ottinger@swedish.org", 
                    "last_name": "Lauren Lennox", 
                    "phone": "206-320-7115"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98104"
                    }, 
                    "name": "Swedish Cancer Institute Swedish Cancer Institute (SC)"
                }, 
                "investigator": {
                    "last_name": "Frances Broyles", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brugge", 
                        "country": "Belgium", 
                        "zip": "8310"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bruxelles", 
                        "country": "Belgium", 
                        "zip": "1200"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edegem", 
                        "country": "Belgium", 
                        "zip": "2650"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "3000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Liege", 
                        "country": "Belgium", 
                        "zip": "4000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Halifax", 
                        "country": "Canada", 
                        "state": "Nova Scotia", 
                        "zip": "B3H 1V7"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N6A 4L6"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H2L 4M1"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "zip": "H2W 1T8"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Angers", 
                        "country": "France", 
                        "zip": "49033"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bron Cedex", 
                        "country": "France", 
                        "zip": "69677"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Le Kremlin Bicetre", 
                        "country": "France", 
                        "zip": "94275"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "LILLE Cedex", 
                        "country": "France", 
                        "zip": "59037"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75006"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris Cedex 13", 
                        "country": "France", 
                        "zip": "75651"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pierre-Benite Cedex", 
                        "country": "France", 
                        "zip": "69495"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse Cedex 9", 
                        "country": "France", 
                        "zip": "31059"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "10098"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Muenchen", 
                        "country": "Germany", 
                        "zip": "80804"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00fcnchen", 
                        "country": "Germany", 
                        "zip": "80336"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ulm", 
                        "country": "Germany", 
                        "zip": "89081"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "W\u00fcrzburg", 
                        "country": "Germany", 
                        "zip": "97080"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jerusalem", 
                        "country": "Israel", 
                        "zip": "91120"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Petach Tikva", 
                        "country": "Israel", 
                        "zip": "49100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ancona", 
                        "country": "Italy", 
                        "state": "AN", 
                        "zip": "60126"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20149"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20162"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy", 
                        "state": "PD", 
                        "zip": "35128"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "state": "RM", 
                        "zip": "00168"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "M\u00e9xico", 
                        "country": "Mexico", 
                        "state": "Distrito Federal", 
                        "zip": "14269"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Groningen", 
                        "country": "Netherlands", 
                        "zip": "9713 GZ"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint-Petersburg", 
                        "country": "Russian Federation", 
                        "zip": "197341"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Canada", 
                "France", 
                "Germany", 
                "Israel", 
                "Italy", 
                "Mexico", 
                "Netherlands", 
                "Russian Federation"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2023", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The study is expected to remain open for approximately 10 years or until such time that enrolled patients no longer need treatment with pasireotide or are able to obtain commercial supply according to local regulations for their medical condition. A patient will reach the end of study when pasireotide treatment is permanently discontinued.", 
            "measure": "Number of patients receiving pasireotide", 
            "safety_issue": "Yes", 
            "time_frame": "Approximately 10 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01794793"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Collect long term safety data, i.e. SAEs and 'AEs of special interest'. SAES will be reviewed and reported as part of the regular pharmacovigilance activities.", 
            "measure": "Frequency and nature of serious adverse events (SAEs)", 
            "safety_issue": "No", 
            "time_frame": "as necessary up to 10 years"
        }, 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}